A major obstacle in producing clinically relevant hMSCs is the lack of quantifiable protocols for evaluating trilineage differentiation. Current assessments rely on qualitative staining. To shift this from informational to a product release specification, GMP-compliant assays for differentiation need to be developed.
The project will utilize a qRT-PCR method to assess osteogenic, adipogenic, and
chondrogenic differentiation in a GMP test. Once the parameters of these assays are established,
the SOPs and Batch Records will then be tech transferred (TT) to a Contract Testing Organization
(CTO) for QC testing of GMP hMSCs.
Developed a workflow for differentiating hMSCs and identifying specific gene markers for osteogenic, chondrogenic, and adipogenic differentiation.
Verified gene markers across multiple MSC donors, labs, and operators.
Created a cGMP-compatible protocol to quantitatively analyze hMSC differentiation in 14 days, reducing time and cost compared to qualitative assays.
GMP compliant assays for human mesenchymal stem cell (hMSCs) differentiation.
Methods developed will be used to draft standards for differentiation with the Standards Coordinating Body for the entire field of adult stem cell research.
CQAs for product release specification rather than 'for information only.'
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
RoosterBio Inc
Carnegie Mellon University
Tulane University
